Reporting owner · CIK 0001120477

Patel Dinesh V Ph D

Visual SEC Form 4 history across 1 companies, 9 transactions and 6 filings.

PRESPresident and CEOProtagonist Therapeutics, Inc
Open-market mix
Latest filingSep 08, 2026, 09:14 PM
Filings6Form 4 records
Buying$00 purchases
Selling$204.6K1 sales
Net value−$204.6KBuys minus sells
Companies12 securities
Most recentSep 03, 2026gift

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 24Jan 251Feb 25Jan 26Sep 26

Net value flow

Buys minus sells

Jan 24
$0
Jan 25
$0
Feb 25
−$204.6K
Jan 26
$0
Sep 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$204.6K
Median P/S size$204.6K
Direct9
Indirect0
Sep 03, 2026gift

Filing-only signals

Deterministic matches in this insider's history

Derivative Transactionfiling-context3Direct Ownershipfiling-context8Large Holdings Increaseholdings4

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Protagonist Therapeutics, Inc on Feb 19, 2025 valued at $204,607.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Protagonist Therapeutics, Inc on Feb 19, 2025 valued at $204,607.

Review SEC filing

Associated companies

Visual map of known reporting history

PTGXProtagonist Therapeutics, Inc9 transactions · latest Sep 08, 2026, 09:14 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
PTGXPATEL DINESH V PH D
PRES
gift510$0G
Direct Ownership
0.0%09/0809/03
PTGXPATEL DINESH V PH D
PRES
grant120k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
+26.0%01/0701/02
PTGXPATEL DINESH V PH D
PRES
grant95.4k$0A
Direct Ownership
+26.0%01/0701/02
PTGXPATEL DINESH V PH D
PRES
sale5.35k-$20.4MS
Direct Ownership
—02/20/202502/19/2025
PTGXPATEL DINESH V PH D
PRES
withholding12.6k$0F
Direct Ownership
—01/17/202501/15/2025
PTGXPATEL DINESH V PH D
PRES
grant181k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/06/202501/02/2025
PTGXPATEL DINESH V PH D
PRES
grant149k$0A
Direct Ownership Large Holdings Increase
—01/06/202501/02/2025
PTGXPATEL DINESH V PH D
PRES
grant315k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/04/202401/02/2024
PTGXPATEL DINESH V PH D
PRES
grant84.8k$0A
Direct Ownership
—01/04/202401/02/2024

Patel Dinesh V Ph D Insider Activity FAQ

SEC Form 4 context

Who is Patel Dinesh V Ph D?

Patel Dinesh V Ph D is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001120477.

Which companies has Patel Dinesh V Ph D reported transactions for?

Protagonist Therapeutics, Inc

When was Patel Dinesh V Ph D's latest insider buy?

No open-market insider purchase is available for this period.

When was Patel Dinesh V Ph D's latest insider sale?

sale at Protagonist Therapeutics, Inc on Feb 19, 2025 valued at $204,607.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.